BioVenture

Hengyu Medical is a medical device firm focused on R&D and production of IVUS and optical coherence tomography, and catheter equipment.

Degron Therapeutics is a drug discovery company focused on developing a new class of therapeutics centered around targeted protein degradation. The company specializes in molecular glue degrader drugs, which are small molecules designed to selectively target and degrade specific proteins associated with various diseases. Degron Therapeutics aims to lead the field of small molecule molecular glue degrader medicines by leveraging its expertise to identify and validate challenging disease targets that traditional small molecule inhibitors cannot effectively address. The company is committed to addressing unmet medical needs across a broad range of therapeutic areas by developing innovative protein degradation drugs, utilizing its advanced molecular glue platform technology to enhance treatment efficacy.

MyoGene Life Sciences is a regenerative medical company that specializes in the promotion of its regenerative repair material product line for bone repair.

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, AusperBio aims to deliver effective targeted therapies that leverage antisense oligonucleotide technology. The company is dedicated to transforming the treatment landscape for hepatitis B, with an emphasis on finding a cure and providing protection through novel therapeutic approaches. Additionally, AusperBio's research extends to addressing a variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, thereby broadening the potential impact of its therapeutic innovations.

Yili Pharmaceutical is a pharmaceutical R&D company that mainly engages in biochemical product technology R&D, medical research and experimental development, engineering and technology research and experimental development, and software development.

Allink Biotherapeutics is a biopharmaceutical company that focuses on oncology and immunological treatment.

Macrolux Medical is a medical technology company that specializes in endoscopic interventional solutions. It focuses on developing devices for both diagnosis and treatment across various medical fields, including urology, respiratory, and digestive health. By promoting these innovative solutions to a wide range of medical customers, Macrolux aims to enhance patient outcomes through earlier detection and improved treatment options. The company's commitment to advancing endoscopic therapy positions it as a key player in the medical device sector.

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, AusperBio aims to deliver effective targeted therapies that leverage antisense oligonucleotide technology. The company is dedicated to transforming the treatment landscape for hepatitis B, with an emphasis on finding a cure and providing protection through novel therapeutic approaches. Additionally, AusperBio's research extends to addressing a variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, thereby broadening the potential impact of its therapeutic innovations.

Secretech is a research and development-driven biotechnology company focused on creating biomarkers and cellular exosomes. It specializes in developing a molecular detection technology platform designed to offer innovative solutions across scientific, clinical, and drug discovery sectors. The company is dedicated to advancing a new generation of molecular detection methods, integrated with advanced computational biology algorithms. This approach enables Secretech to deliver robust proteomics analysis tools that facilitate the rapid discovery of new molecular markers.

Changsha Morning Shine is an innovative pharmaceutical company that specializes in R&D outsourcing, biomedicine, chemical drugs, and biotechnology services.

Shenzhen CardioACC Ltd specializes in advanced cardiovascular interventional, natural cavity imaging and advanced diagnostic procedures.

Shanghai Kechow Pharma is a biopharmaceutical company based in Shanghai that pursues novel drug discovery with a focus on oncology. It develops targeted small molecule therapies and participates in co-development with partners, covering research, clinical development, and regulatory registration. Founded in 2014, the company emphasizes creating new anti-cancer drugs to address clinical needs and strives to bring high-quality oncology treatments to patients.

Gene Cradle is a genetic company that develops gene therapy drugs to treat rare genetic diseases as well as chronic diseases.

Jiamuyao Medical specialized in developing an energy platform for the comprehensive treatment of complex intravascular lesions.

Suzhou Panomic Biomedical Technology Co., Ltd. (BioNovoGene) was founded in Suzhou Industrial Park Bio-Nano Park in 2013. It is a leading high-tech enterprise focusing on metabolomics in China. Since its establishment, it has established a complete metabolomics detection and analysis platform - PanomicTM / Bionovogene, including metabolite preprocessing platform, high-resolution mass spectrometry analysis platform, and metabolomics data analysis with independent intellectual property rights The system has perfect biomarker discovery capabilities and clinical application capabilities. The company's scientific research team has a rich background, covering biochemistry, bioinformatics, epidemiology and biostatistics, computer science, etc., and has a consultant team composed of top scientists and clinicians.

XellSmart is a company based in Minhang District, Shanghai, China, focused on developing stem cell treatment solutions for various degenerative diseases that currently lack effective clinical treatments. The firm aims to enhance disease treatment and facilitate drug discovery through innovative stem cell therapies. XellSmart is dedicated to offering large-scale and cost-effective stem cell treatment, replacement, and transplantation options, specifically targeting major conditions like Parkinson's disease. By advancing these solutions, XellSmart seeks to provide patients with viable clinical alternatives to improve their health outcomes.

Ruoyi Biotech is a developer of macromolecular drug delivery technology.

Innovision is a company that specializes in developing auxiliary diagnosis and treatment systems tailored for endoscopy centers in hospitals. By leveraging artificial intelligence deep learning technology, Innovision processes digestive endoscopy image data to assist in medical imaging-assisted diagnosis of the digestive system. This innovative approach helps hospitals enhance work efficiency and alleviate the workload on endoscopy doctors, ultimately reducing the need for redundant labor.

Human Zhizao is a technology platform that provides comprehensive diagnostic solutions. They provide clinical customers with a parallel, full-automatic multiple flow cytometry fluorescence detection platform and supporting reagents. They provide customer service. The flow fluorescence luminescence technology is a new generation of throughput detection and analysis platform integrating flow analysis, laser analysis, digital signal processing, and other technologies. They involve projects that require the joint detection of multiple indicators, such as autoantibodies, allergens, cytokines, etc.

Lealing Biotech developes anti-body based drugs and pharmaceutical products.

Hanchao Pharmaceutical is a biopharmaceutical company that specializes in the development and production of medical equipment and solutions for the biomedical industry. The company's core focus is on providing single-use bioprocessing solutions, with a particular emphasis on biomedical production technology. Hanchao independently designs, manufactures, and sells a range of equipment and consumables, catering to the industrialization stage of various biomedical fields, including antibodies, vaccines, antibody-drug conjugates (ADCs), and cell and gene therapies (CGTs).

ProxyBio develops treatment and pharmaceutical products for mRNA development.

Pulnovo Medical, established in 2013 in Wuxi, Anhui, is focused on the development, production, and service provision of innovative medical technologies. The company specializes in creating advanced equipment for treating pulmonary hypertension, particularly through the use of pulse radiofrequency ablation technology. Its core products include pioneering high-frequency ablation equipment and intravascular catheters, which are protected by global invention patents. Pulnovo Medical aims to enhance the quality of life for patients suffering from pulmonary hypertension and heart failure by offering cutting-edge treatment solutions.

NeuShen Therapeutics develops therapies for neurological and psychiatric disorders by integrating small molecule discovery with AAV-based gene therapy. The company's platform combines therapeutic compounds and gene delivery systems to address central nervous system conditions through targeted mechanisms, scalable clinical development, and a dual-modality approach that supports precision medicine and broad therapeutic applicability.

Cell Probio is a manufacturer of cell culture consumables, positioned in the R&D, production and sales of high-end biological consumables.

Zhongguancun Shuimu Medical Technology is the operator of a third-party, competent medical device compliance organization. Their business helps companies cut costs and time to market by offering medical device compliance services. It is dedicated to accelerating the registration and listing procedures for new medical device items as well as addressing the issue of how to industrialize creative medical device firms.

Future Vision is a visual health service organization based in Shanghai, specializing in the prevention and control of myopia, amblyopia rehabilitation training, and medical optometry for children aged 3 to 16. The company utilizes advanced North American optometry technology to deliver its services, aiming to address the growing concerns of visual health among children. By focusing on early intervention and comprehensive eye care, Future Vision seeks to improve the visual outcomes for its young clientele.

Degron Therapeutics is a drug discovery company focused on developing a new class of therapeutics centered around targeted protein degradation. The company specializes in molecular glue degrader drugs, which are small molecules designed to selectively target and degrade specific proteins associated with various diseases. Degron Therapeutics aims to lead the field of small molecule molecular glue degrader medicines by leveraging its expertise to identify and validate challenging disease targets that traditional small molecule inhibitors cannot effectively address. The company is committed to addressing unmet medical needs across a broad range of therapeutic areas by developing innovative protein degradation drugs, utilizing its advanced molecular glue platform technology to enhance treatment efficacy.

Resproly specializes in the research, development, production, and sales of respiratory inhalation formulas and equipment. The company focuses on clinically demanding treatment areas such as asthma, COPD (Chronic Obstructive Pulmonary Disease), diabetes, and Parkinson's disease.

Juncell Therapeutics is a biopharmaceutical company focused on developing innovative therapies for tumor treatment. The company specializes in tumor cell therapy, offering solutions to isolate tumor-infiltrating lymphocytes (TILs) from tumor tissues. These TILs are then cultivated outside the human body before being reintroduced to patients, aiming to enhance the body's ability to combat tumors while minimizing side effects. Through its research and development efforts, Juncell Therapeutics seeks to advance treatment options in the medical industry, ultimately improving patient outcomes in cancer therapy.

Junsai Shengwu developes therapies for new solid tumor cell.

Shengshi Technology is a specialized platform focused on experimental simulation using computational fluid dynamics (CFD) and artificial intelligence for medical engineering research, particularly related to cardiovascular diseases. The company develops non-invasive precision diagnostic and treatment solutions, leveraging advanced technologies such as external fluid dynamics experimental simulation and CFD numerical simulation. By integrating these key technologies, Shengshi Technology aims to enhance the quality of healthcare services for both doctors and patients, ultimately improving outcomes in the management of cardiovascular conditions.

Guangwei Pharmaceuticals is a pharmaceutical manufacturer in China that produce medical theater products.

InnoBM Pharmaceuticals is a company specializing in the development of biomaterials and pharmaceutical products. It focuses on creating novel therapeutics aimed at enhancing the efficacy of tumor immunotherapy, thereby addressing critical needs in cancer treatment. By committing to innovation, InnoBM Pharmaceuticals strives to improve outcomes for cancer patients through advanced therapeutic solutions.

Yuanjingtaico is a biotech firm focused on the R&D of fluorescent PCR reagents, microfluidic, and electrochemical detection products.

Beijing Changmugu Medical Technology Co., Ltd. is a healthcare start-up that specializes in developing artificial intelligence-powered solutions for medical and surgical applications. Based in Beijing, China, the company focuses on enhancing orthopedic procedures through advanced technology. It offers a range of services including AI-assisted diagnosis, individualized surgical planning, 3D printing for patient-specific instrumentation, and post-operative evaluation. By leveraging deep learning algorithms, Changmugu Medical aims to improve the precision and safety of orthopedic surgeries, ultimately providing patients with more secure and reliable treatment options.

Comma Bio is a comprehensive solution provider for sample pretreatment. Based on two types of snap-neck material technologies of adsorption and separation materials and filter materials, the company has created three major technology platforms for porous plastics, separation materials and precision injection molding. Customers in the fields of, precision medicine, analysis and testing provide comprehensive solutions for sample pre-processing.

Hopstem Biotechnology LLC is a Houston-based company that focuses on the development of neural stem cell technology and stem cell therapies specifically for neurological disorders. Established in 2019, the company specializes in the neural differentiation, cell banking, and cell engineering of human induced pluripotent stem cells (iPSCs) and human embryonic stem cells (ESCs). By leveraging its advanced technologies, Hopstem aims to enhance biomedical research and improve diagnostic and therapeutic options for various neurological conditions. Through its innovative approaches, the company seeks to provide effective treatment solutions for patients suffering from these disorders.

Bioligo, officially known as Shanghai Bailige Biotechnology Co., Ltd., is a biotechnology company specializing in the provision of high-quality DNA synthesis and sequencing services. The company focuses on serving the genetic and molecular diagnostics sector, which is integral to the field of precision medicine. Bioligo offers a range of products, including DNA primers, fluorescently labeled probes, and RNA synthesis products. Additionally, they supply essential materials for next-generation sequencing library construction, such as adapters, blocking agents, and target capture probes. By addressing critical gaps in raw materials, Bioligo supports its downstream customers in the in vitro diagnostic industry, enhancing their capabilities in precision medicine applications.

Boan Biotech is a biopharmaceutical company focused on developing therapeutic antibodies for oncology, metabolism, autoimmunity, and ophthalmology. It conducts development, manufacturing, and commercialization of biologics and serves customers in China and international markets, with operations based in Shandong, China.

Vision X is a solutions provider for medical equipment in the field of ophthalmology and optometry.

Reforgene Medicine is a biomedical company focused on developing innovative drugs aimed at curing genetic diseases, chronic illnesses, and cancer. Utilizing advanced gene editing and genomic technologies, the company creates programmable medicine that offers targeted treatments for patients. By harnessing the potential of genome editing, Reforgene Medicine seeks to improve patient outcomes and contribute to the advancement of personalized healthcare solutions.

Alebund Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies for renal diseases and associated chronic conditions. The company focuses on researching and commercializing treatments for a variety of kidney-related ailments, including chronic kidney disease, dialysis complications, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified pipeline of drug candidates, Alebund Pharmaceuticals aims to deliver comprehensive, high-quality solutions to patients suffering from renal diseases, addressing both immediate and long-term healthcare needs in this critical area.

NeuExcell Therapeutics is an early-stage gene therapy company dedicated to addressing neurodegenerative diseases and neural injuries. The company has developed an innovative neural repair technology that facilitates the conversion of astrocytes into neurons through in vivo methods. By employing adeno-associated virus-based gene therapy to introduce neural transcription factors, NeuExcell aims to enable clinicians to restore damaged neural tissue. The company's mission is to enhance the quality of life for millions of patients worldwide who are affected by neurodegenerative conditions.

Hopstem Biotechnology LLC is a Houston-based company that focuses on the development of neural stem cell technology and stem cell therapies specifically for neurological disorders. Established in 2019, the company specializes in the neural differentiation, cell banking, and cell engineering of human induced pluripotent stem cells (iPSCs) and human embryonic stem cells (ESCs). By leveraging its advanced technologies, Hopstem aims to enhance biomedical research and improve diagnostic and therapeutic options for various neurological conditions. Through its innovative approaches, the company seeks to provide effective treatment solutions for patients suffering from these disorders.

Suzhou Panomic Biomedical Technology Co., Ltd. (BioNovoGene) was founded in Suzhou Industrial Park Bio-Nano Park in 2013. It is a leading high-tech enterprise focusing on metabolomics in China. Since its establishment, it has established a complete metabolomics detection and analysis platform - PanomicTM / Bionovogene, including metabolite preprocessing platform, high-resolution mass spectrometry analysis platform, and metabolomics data analysis with independent intellectual property rights The system has perfect biomarker discovery capabilities and clinical application capabilities. The company's scientific research team has a rich background, covering biochemistry, bioinformatics, epidemiology and biostatistics, computer science, etc., and has a consultant team composed of top scientists and clinicians.

Brattea is a medical device research and development company specializing in renal denervation products aimed at addressing various health conditions, including hypertension, cancer pain, and diabetes. The company develops interventional devices that include renal artery ablation catheters, radiofrequency ablation equipment, and medical mapping systems. These products are designed to treat a range of medical issues, such as refractory hypertension, obstructive sleep apnea, kidney disease, and heart failure. Through its innovative approach, Brattea aims to provide reliable solutions that improve patient outcomes and enhance the quality of care in the medical field.

Pro-Heal Pharmaceuticals is a biotechnology company that specializes in the development and manufacturing of pharmaceutical products. It focuses on creating drugs for ophthalmic and autoimmune diseases, addressing critical needs in the pharmaceutical field. By concentrating on biological macromolecule therapies and ophthalmology medicines, Pro-Heal aims to provide effective treatments that are currently lacking in clinical settings, thereby improving patient outcomes. The company's commitment to innovation and development positions it as a valuable player in the healthcare industry, dedicated to meeting urgent medical needs.

Beijing Changmugu Medical Technology Co., Ltd. is a healthcare start-up that specializes in developing artificial intelligence-powered solutions for medical and surgical applications. Based in Beijing, China, the company focuses on enhancing orthopedic procedures through advanced technology. It offers a range of services including AI-assisted diagnosis, individualized surgical planning, 3D printing for patient-specific instrumentation, and post-operative evaluation. By leveraging deep learning algorithms, Changmugu Medical aims to improve the precision and safety of orthopedic surgeries, ultimately providing patients with more secure and reliable treatment options.

Kyinno is a biopharmaceutical company specializing in the development of oncology drugs. Its focus lies in immune treatments against cancer and next-generation kinase inhibitor design.

Huikai Medical is a specialized manufacturer and developer of minimally invasive urological medical devices. Its product portfolio focuses on addressing key urinary system conditions such as prostatic hyperplasia, urinary stones, incontinence, and urological tumors. The company's innovative devices are designed to enhance patient comfort and efficiency in medical settings, utilizing proprietary technology and materials for superior clinical outcomes.

PegBio is a biopharmaceutical company based in Suzhou, focused on polyethylene glycol (PEG) chemistry and PEGylation technology to develop and manufacture PEGylated drugs as potential new molecule entities. The company offers PEG synthesis and PEGylation services, including N-terminal specific, thiol-selective, and enzymatic PEGylation, along with pharmaceutical-grade PEGs and activated PEGs for research and pharmaceutical applications. It provides PEGylation services to universities, research institutes, and pharmaceutical companies and develops PEGylated peptides and antibody fragments for therapeutic areas such as type II diabetes and rheumatoid arthritis. PegBio also develops PB-119, a glucagon-like peptide-1 (GLP-1) receptor agonist designed for less frequent dosing, and engages in collaborations with strategic partners to modify macromolecules and advance PEGylated biopharmaceuticals.

Shanghai OMNI Pharmaceutical Technology Co., Ltd. is a pharmaceutical company based in Shanghai, China, specializing in the research, development, and manufacturing of respiratory products. Founded in 2006, OMNI focuses on both generic and branded pharmaceuticals aimed at treating chronic diseases such as Chronic Obstructive Pulmonary Disease (COPD) and asthma. The company offers a range of dosage forms, including inhalation dry powders, nasal sprays, HFA aerosols, and sustained-release capsules and tablets. OMNI also provides contract manufacturing and clinical research services for complex drug delivery systems that are challenging to develop and manufacture. By leveraging its expertise, the company aims to address public health challenges in regulated markets, including North America, Europe, and China.

Yingsheng Biotechnology Co., Ltd., established in 2009, specializes in the development of in vitro diagnostic reagents and medical equipment focused on maternal and child health, neonatal genetic diseases, metabolic disorders, and birth defects. The company offers a diverse product line that includes 45 innovative screening reagents for genetic metabolic diseases, deaf genetic testing kits, vitamins determination reagents, and an HLA-B27 detection kit. Yingsheng also provides advanced diagnostic technologies such as a mass spectrometer automatic intelligent processing platform and ultra-high performance liquid chromatography tandem mass spectrometry detection systems. Through its innovative products, Yingsheng aims to facilitate early detection of genetic conditions, promoting timely intervention and better health outcomes for patients.

GensKey is a medical diagnostic service provider specializing in genetic testing for pathogen diagnosis. The company utilizes high-throughput sequencing technology combined with intelligent algorithm analysis to address challenges associated with traditional diagnostic methods, such as low detection rates, lengthy processes, and accuracy issues. By improving the timeliness and precision of pathogen diagnosis, GensKey enables patients suffering from severe infections to receive prompt and reliable diagnoses, thereby enhancing the potential for effective treatment and recovery.

Beijing Delta Medical Co., Ltd. specializes in the design and manufacture of orthopedic surgical instruments and rehabilitation products. The company offers a range of products, including shoulder arthroscopic instruments, various types of suture anchors, instruments for anterior and posterior cruciate ligament reconstruction, interference screws, and shaver systems. In addition to its surgical instruments, Delta Medical provides sports rehabilitation services. The company is headquartered in Beijing, China, and focuses on delivering innovative solutions in sports medicine.

Zhejiang Pushikang Biotechnology offer In-vitro diagnostics solutions.

X-ABT is a tech enterprise that provides solutions for pathogenic microorganism detection in the medical and health fields. The company focuses on providing complete solutions for the detection of infectious pathogens in the medical and health field. They develop and produce systems for disease control, prevention, clinical hospitals, and entry-exit customs. X-ABT also provides clinical marketing and sales services to help medical workers and serve patients.

Shanghai Bioheart Biotechnology Co., Ltd., established in 2014 and located in Shanghai, China, specializes in the development of drug-eluting stents. The company is focused on creating innovative, high-value minimally invasive therapeutic products. Bioheart aims to enhance medical technology and provide superior healthcare solutions for medical professionals and patients alike, positioning itself as a significant player in the medical and healthcare industry.

RainSure Scientific is a medical-based manufacturing company that produces PCR instruments, assays, and healthcare services.

Just Medical is a developer and manufacturer of artificial orthopedic implant devices and systems, specializing in products such as artificial hip and knee joints, internal fixation products, and orthopedic surgical instruments. The company is dedicated to enhancing surgical efficiency and improving the quality of orthopedic treatment through advanced technology research and development. Just Medical focuses on creating safe and effective medical products and services, continually refining its product system to address the needs of healthcare providers and alleviate patient pain. Its commitment to high-speed development and excellence positions it as a key player in the orthopedic medical device industry.

Yingsheng Biotechnology Co., Ltd., established in 2009, specializes in the development of in vitro diagnostic reagents and medical equipment focused on maternal and child health, neonatal genetic diseases, metabolic disorders, and birth defects. The company offers a diverse product line that includes 45 innovative screening reagents for genetic metabolic diseases, deaf genetic testing kits, vitamins determination reagents, and an HLA-B27 detection kit. Yingsheng also provides advanced diagnostic technologies such as a mass spectrometer automatic intelligent processing platform and ultra-high performance liquid chromatography tandem mass spectrometry detection systems. Through its innovative products, Yingsheng aims to facilitate early detection of genetic conditions, promoting timely intervention and better health outcomes for patients.

Allist Pharmaceuticals is a pharmaceutical company based in Shanghai that focuses on discovering, developing, and commercializing innovative medicines, particularly in the field of cancer treatment. The company is driven by the unmet clinical needs within the global pharmaceutical market and is committed to advancing long life through scientific and technological innovation. Allist Pharmaceuticals aims to create safe, effective, and inclusive drugs, holding independent intellectual property rights for its products.

Kanglu Bio is positioned to provide clinical diagnosis and guidance for clinical drug molecular diagnostic products and clinical molecular diagnostics overall service providers for clinical hospitals and third-party clinical independent testing institutions. The products and services are mainly used in cardiovascular and cerebrovascular diseases. Major diseases such as tumors and cancer.

CART Medical Technologies is a high-tech company focused on advancing immune cell therapy through innovative technologies. The company specializes in developing CAR-T cells, which can target both protein antigens and glycolipid non-protein antigens, thereby expanding the range of tumor antigen targets. This approach enhances T-cell generation and activation, leading to more effective treatments for various diseases. CART Medical operates out of a 2,200 square meter facility that includes GMP laboratory and research and development laboratories.

Isia Biotech is a developer and producer of in vitro diagnostic (IVD) medical technology that focuses on detecting and diagnosing diseases through immune reactions. The company utilizes its proprietary quantum dot technology to enhance the accuracy of tests for various medical conditions, including cardiovascular disease, inflammation, bone metabolism, gastric function, renal function, cancer, and other autoimmune diseases. By advancing diagnostic capabilities, Isia Biotech aims to support healthcare providers in improving disease detection, diagnosis, and treatment. Their commitment to research and development, alongside the production and sales of diagnostic instruments, positions them as a significant player in the medical technology sector.

Shanton Pharma Co., Ltd. is a biotechnology research organization founded in 2016 and based in Shanghai, China. The company specializes in the research and development of innovative therapies aimed at addressing significant unmet medical needs, with a particular focus on uric acid metabolism, inflammatory pain, and gout metabolic syndrome diseases. Shanton Pharma has dedicated substantial efforts to the field of gout diseases, where it has developed a promising product, SAP-001, which has demonstrated safety and efficacy. The company aims to commercialize its core products and deliver innovative new medicines to patients and the medical community.

Kanova is a biopharmaceutical company dedicated to the development of therapeutic antibodies and innovative combination therapies, specifically targeting immuno-oncology and autoimmune diseases. The company offers a biomedical technology service platform that supports pharmaceutical research and production in the biotechnology sector. By providing antibody-based drugs that enhance immune system functionality, along with technical consultation and drug quality inspection services, Kanova enables its clients to improve drug quality and efficiently advance the field of biomedicine.

Neighbor Doc is an online platform that offers a range of healthcare services, aiming to transform community medical care by integrating general practice and specialty services. The organization focuses on providing convenient access to both online and offline medical consultations, covering various fields such as pediatrics, dental care, gynecology, and complex surgical procedures. With a commitment to affordability and quality, Neighbor Doc seeks to establish a comprehensive healthcare network that enhances the capabilities of community medical services, thereby ensuring that patients receive the necessary care in a timely and efficient manner.

Beijing Delta Medical Co., Ltd. specializes in the design and manufacture of orthopedic surgical instruments and rehabilitation products. The company offers a range of products, including shoulder arthroscopic instruments, various types of suture anchors, instruments for anterior and posterior cruciate ligament reconstruction, interference screws, and shaver systems. In addition to its surgical instruments, Delta Medical provides sports rehabilitation services. The company is headquartered in Beijing, China, and focuses on delivering innovative solutions in sports medicine.

Ningbo Senscure Biotechnology Co., Ltd specializes in the innovation and enhancement of minimally invasive surgery technologies, focusing primarily on single incision laparoscopic surgery (SILS) and natural orifice transluminal endoscopic surgery (NOTES). The company is dedicated to tumor treatment and offers a range of surgical devices, including a laparoscopic single port multi-channel access platform, a pulmonary nodule localization needle, a tumor cryoablation system, and an anti-gastroesophageal reflux system. Senscure provides comprehensive medical equipment solutions designed to facilitate minimally invasive surgeries.

Claricare Medical is an innovative developer of oncology vascular interventional therapeutic services.

Smartee Denti-Technology, established in 2004, specializes in developing and manufacturing invisible orthodontic systems. The company's flagship product, the Smartee aligner, combines 3D printing, CAD, and CAM technologies to accurately move teeth without the need for traditional braces. With over 23.6 million sets of aligners delivered worldwide, Smartee has a strong presence in China and serves global markets. The company employs over 1,700 people, including a medical team of over 380 professionals, and has obtained more than 500 patents. Smartee is recognized for its innovation and contributions to the Chinese invisible orthodontic industry, holding memberships in various industry associations and collaborations with renowned institutions like the University of North Carolina and China Aerospace.

POCTech Medical develops a CGM sensor product for the diabetes care communities.

Ark Biosciences Inc. is a biopharmaceutical company based in Shanghai, China, specializing in the discovery and development of therapeutics aimed at addressing unmet medical needs, particularly in the areas of respiratory viral infections and viral hepatitis. Founded in 2013, the company focuses on developing innovative treatments, including AK0701 for chronic obstructive pulmonary disease, AK0529 for respiratory syncytial virus, AK0612 for influenza, and AK0705 and AK0706 for hepatitis B. Ark Biosciences is committed to advancing antiviral drug research and development to serve both global and Chinese markets.

Genowise is a company specializing in advanced genetic testing and medical diagnostic services. It offers a range of services, including pharmacogenomics, auxiliary diagnosis, and tumor genome diagnosis. Genowise has developed next-generation gene sequencing reagents and a clinical data analysis system to enhance the effectiveness of genetic testing. The company provides over 15 different genetic testing kits that cover more than 170 diseases and assess over 810 known gene loci, facilitating better health management for patients. Through its innovative approach, Genowise aims to improve diagnostic accuracy and support personalized medicine initiatives.

Shanghai Kechow Pharma is a biopharmaceutical company based in Shanghai that pursues novel drug discovery with a focus on oncology. It develops targeted small molecule therapies and participates in co-development with partners, covering research, clinical development, and regulatory registration. Founded in 2014, the company emphasizes creating new anti-cancer drugs to address clinical needs and strives to bring high-quality oncology treatments to patients.

Eddingpharm, established in 2001, is a pharmaceutical company focused on supplying high-quality patented and branded drugs to the Chinese healthcare market. The company aims to bridge the gap between Chinese patients and global medicines by acquiring classic branded medications from multinational corporations and introducing innovative patented drugs. Eddingpharm has rapidly expanded its operations across China, deploying nearly 1,000 professional representatives in 30 provinces, with access to over 19,000 hospitals and 20,000 pharmacies. Its collaborations with multinational pharmaceutical companies and leading research institutions have enriched its product portfolio, particularly in therapy areas such as oncology, cardiovascular, respiratory, and renal diseases. A notable product in its line is Vascepa®, a prescription medication that lowers triglyceride levels without raising LDL cholesterol. Eddingpharm has been granted development and commercialization rights for Vascepa® in mainland China, Hong Kong, Macau, and Taiwan, and is currently conducting clinical trials to support its regulatory registrations. The company's commitment to professionalism, excellence, responsibility, and persistence underpins its mission to enhance treatment options for patients in China.

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, AusperBio aims to deliver effective targeted therapies that leverage antisense oligonucleotide technology. The company is dedicated to transforming the treatment landscape for hepatitis B, with an emphasis on finding a cure and providing protection through novel therapeutic approaches. Additionally, AusperBio's research extends to addressing a variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, thereby broadening the potential impact of its therapeutic innovations.